ESTRO 2024 - Abstract Book

S2069

Clinical - Paediatric

ESTRO 2024

Palma DA, Olson R, Harrow S, Correa RJM, Schneiders F, Haasbeek CJA, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer. 2019 Aug;19(1):816. 2. Palma DA, Olson R, Harrow S, Gaede S, Louie A V., Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet [Internet]. 2019;393(10185):2051–8. Available from: http://dx.doi.org/10.1016/S0140-6736(18)32487-5

3. Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: A phase 2 randomized clinical trial. JAMA Oncol. 2018;4(1).

4. Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, DeBruycker A, et al. Surveillance or metastasis directed therapy for oligometastatic prostate cancer recurrence: A prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36(5):446–53. 5. Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol. 2020;6(5):650–9. 6. Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, et al. Local Consolidative Therapy versus Maintenance Therapy/ Observation for Patients with Oligometastatic Non-Small Cell Lung Cancer without Progression after Front-Line Systemic Therapy: Results of a Multi-Institutional Phase II Randomized Study. Lancet Oncol [Internet]. 2017;17(12):1672–82. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27789196%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid= PMC5143183 7. Dingemans AMC, Hendriks LEL, Berghmans T, Levy A, Hasan B, Faivre-Finn C, et al. Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report. J Thorac Oncol [Internet]. 2019;14(12):2109–19. Available from: https://doi.org/10.1016/j.jtho.2019.07.025

3089

Digital Poster

LOCAL CONTROL AND LONG TERM TOXICITY IN SPINAL METASTASES TREATED WITH SRT

Maria Grazia Carnevale 1 , Mauro Loi 1 , Gabriele Simontacchi 1 , Victoria Lorenzetti 1 , Daniela Greto 1 , Emanuela Olmetto 1 , Pietro Garlatti 1 , Icro Meattini 1 , Erika Scoccimarro 1 , Giulio Francolini 1 , Luca Visani 1 , Vanessa DiCataldo 1 , Viola Salvestrini 1 , Pierluigi Bonomo 1 , Anna Peruzzi 1 , Beatrice Bettazzi 1 , Marianna Valzano 1 , Marta Casati 2 , Chiara Arilli 2 , Lorenzo Livi 1 1 Azienda Ospedaliero Universitaria Careggi, Università di Firenze, Radiation Oncology, Florence, Italy. 2 AOU Careggi Florence, Medical Physics Unit, Florence, Italy

Purpose/Objective:

Stereotactic radiotherapy (SRT) has emerged as a promising treatment modality for spine bone metastases. As opposed to conventional radiotherapy (CRT), it delivers high doses of radiation to the target volume in a shorter